Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8030397 | 0.77 | MAOA (0.43) | NOTUMIDO1AKR1C3LIPEMAOA | |
| SCHEMBL15222058 | 0.77 | MAOA (0.43) | NOTUMIDO1AKR1C3LIPEMAOA | |
| SCHEMBL8324725 | 0.77 | MAOA (0.43) | NOTUMIDO1AKR1C3LIPEMAOA | |
| SCHEMBL26639288 | 0.76 | SIGMAR1 (0.37) | — | |
| SCHEMBL18681676 | 0.75 | DRD3 (0.38) | NOTUMMAOAMAOB | |
| SCHEMBL18681677 | 0.75 | DRD3 (0.38) | NOTUMMAOAMAOB | |
| SCHEMBL18681678 | 0.75 | DRD3 (0.38) | NOTUMMAOAMAOB | |
| SCHEMBL26639025 | 0.74 | DRD2 (0.38) | — | |
| Hydrochloric Acid SCHEMBL7552914 | 0.73 | IDO1 (0.45) | NOTUMIDO1AKR1C3LIPEMAOA | |
| SCHEMBL14705297 | 0.72 | NOTUM (0.55) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | NOTUM 4556/4885IDO1 938/4885AKR1C3 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.